Health and Healthcare
GE Taking Decisive Step Into Stem Cells (GE, GERN, STEM, ASTM)
Published:
Last Updated:
General Electric Company (NYSE: GE) is taking a bold and controversial new step into the field of embryonic stem cell research. The company has signed an exclusive license and alliance pact with Geron Corporation (NASDAQ: GERN) to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening. As noted over at BioHealthInvestor.com, this may have implications for other stem cell stocks such as StemCells Inc. (NASDAQ: STEM), Aastrom Biosciences, Inc. (NASDAQ: ASTM) and others.
The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. While financial terms were not disclosed, this is a major endorsement for Geron and will only add to its position as one of the leaders in the field of stem cell companies in the U.S.
This is a further step in GE Healthcare’s cell technology strategy and is meant to accelerate the development of hESC-derived products for drug discovery and development. GE Healthcare has been granted an exclusive license under Geron’s extensive intellectual property portfolio, which covers the growth and differentiation of hESCs, as well as a sublicense under Geron’s rights to the foundational hESC patents held by the Wisconsin Alumni Research Foundation.
This is being dubbed a multi-year alliance and GE Healthcare will fund the R&D program and will be responsible for manufacturing, sales and distribution of products developed under the agreement. Intellectual property rights that come out of the alliance program research will be shared, with GE Healthcare receiving rights for the development of drug discovery technologies and Geron receiving rights for cell therapy applications.
GE shares were up almost 1% before consumer confidence was released, but Geron is the real winner here with shares up 18% at $7.99 on the day.
The benefits of this could be the next Holy Grail in biotech. Stem cell research is hoped to lead into solid cures such as cancer, cardiac science, tissue regeneration, paralysis, and more. There has long been a ban on new embryonic stem cell lines which was lifted earlier this year. And then there is the controversy of the use of embryonic stem cells that crosses politics, morality, and religion.
Jon C. Ogg
June 30, 2009
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
